NovImmune has agreed an exclusive licensing agreement with Genentech, a member of the Roche Group, to develop a proprietary anti-IL-17 fully human monoclonal antibody.
The IL-17 signalling pathway has received significant academic and corporate interest of late due to its high potential for manipulation and potential new treatment opportunities.
The antibody is currently in late pre-clinical development.
Under the agreement, NovImmune will receive an upfront payment and will eligible to receive clinical milestones and royalties on sales. Financial terms were not disclosed.
Share this article
